Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BBO-11818 |
| Trade Name | |
| Synonyms | BBO 11818|BBO11818 |
| Drug Descriptions |
BBO-11818 is a selective pan-KRAS inhibitor with activity against KRAS variants including G12D and G12V, potentially leading to decreased tumor cell proliferation and reduced tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4378). |
| DrugClasses | KRAS G12D Inhibitor 25 KRAS Inhibitor 30 |
| CAS Registry Number | NA |
| NCIT ID | C216081 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BBO-11818 | BBO-11818 | 0 | 1 |
| BBO-11818 + Carboplatin + Pembrolizumab + Pemetrexed Disodium | BBO-11818 Carboplatin Pembrolizumab Pemetrexed Disodium | 0 | 1 |
| BBO-11818 + Cetuximab | BBO-11818 Cetuximab | 0 | 1 |
| BBO-11818 + Cisplatin + Pembrolizumab + Pemetrexed Disodium | BBO-11818 Cisplatin Pembrolizumab Pemetrexed Disodium | 0 | 1 |
| BBO-11818 + Pembrolizumab | BBO-11818 Pembrolizumab | 0 | 1 |